{"url_path":"/sec/mlab/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/724004/0000724004-26-000047-index.html","accession_number":"0000724004-26-000047","cik":"0000724004","ticker":"MLAB","issuer_name":"MESA LABORATORIES INC /CO/","edgar_url":"https://www.sec.gov/Archives/edgar/data/724004/0000724004-26-000047-index.html","primary_entity_key":"0000724004","primary_entity_name":"MESA LABORATORIES INC /CO/"},"word_count":409,"has_tables":true,"body_markdown":"**Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**\n\n \n\nOur common stock is traded on the Nasdaq Global Market (“Nasdaq”) under the symbol “MLAB.”\n\n \n\nWhile we have paid dividends to holders of our common stock on a quarterly basis since 2003, the declaration and payment of future dividends will depend on many factors, including, but not limited to, our earnings, financial condition, business development needs and regulatory considerations, and will be at the sole discretion of our Board of Directors. At this time, we expect to continue paying dividends commensurate with our historical practice. \n\n \n\nAs of March 31, 2026, there were 53 holders of record of our common stock. This amount does not include “street name” holders or beneficial holders of our common stock, who hold their shares through banks, brokers or other financial institutions.\n\n \n\nDuring the year ended March 31, 2026, we did not sell any equity securities that were not registered under the Securities Act of 1933, as amended.\n\n \n\nOn November 7, 2005, our Board of Directors adopted a share repurchase plan which allows for the repurchase of up to 300,000 of our common shares. This plan will continue until the maximum is reached or the plan is terminated by further action of the Board of Directors. We made no repurchases of our common stock during the years ended March 31, 2026, March 31, 2024, or March 31, 2023. As of March 31, 2026, 137,514 shares remained available to repurchase pursuant to the repurchase plan. \n\n \n\nSee Item 12. *Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters* for information regarding securities authorized for issuance.\n\n \n\nSet forth below is a line graph comparing, for the period March 31, 2021 through March 31, 2026, the cumulative total shareholder return on our common stock against the cumulative total return of (a) the S&P Composite Stock Index (b) the S&P Small Cap 600, and (c) a self-selected peer group, comprised of the following companies: Adaptive Biotechnologies Corporation, Artivion, Inc., AtriCure, Inc., Azenta, Inc., BioLife Solutions, Inc., Codexis, Inc., Cryoport, Inc., Cytek Biosciences, Inc., Haemonetics Corporation, Harvard Bioscience, Inc., Inogen, Inc., LeMaitre Vascular, Inc., Maravai Life Sciences Holdings, Inc., Neogen Corporation, NeoGenomics, Inc., Quanterix Corporation, Standard BioTools, Inc., and Veracyte, Inc. \n\n \n\nThe graph shows the value on March 31 of each year, assuming an original investment of $100 on March 31, 2021 and reinvestment of cash dividends. \n\n \n\n \n\nPage 25\n\n[Table of Contents](#toc)"}